Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.30 +0.42 (+0.73%)
Streaming Delayed Price Updated: 2:53 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,311,973
Open 58.16
Bid (Size) 58.29 (8)
Ask (Size) 58.30 (1)
Prev. Close 57.88
Today's Range 57.47 - 58.48
52wk Range 39.35 - 61.08
Shares Outstanding 2,222,113,553
Dividend Yield 3.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Bristol Myers Squibb Stock a Buy?
Via The Motley Fool
Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Via The Motley Fool

Performance

YTD
+10.50%
+10.50%
1 Month
+11.86%
+11.86%
3 Month
+20.36%
+20.36%
6 Month
+37.69%
+37.69%
1 Year
+20.26%
+20.26%

More News

Read More
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
From Bristol Myers Squibb
Via Business Wire
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Via Benzinga
Not-So-Big Pharma
Via Talk Markets
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 16
Via Talk Markets
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
Via The Motley Fool
2 Beaten-Down Dividend Stocks to Buy and Hold
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Via Benzinga
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
Via Investor's Business Daily
3 Stocks Seeing Insider Buys: CNC, PFE, BMY
Via Talk Markets
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
Via Benzinga
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Via Benzinga
What's Going On With Bristol-Myers Squibb Shares Monday?
Via Benzinga
Dow, S&P 500 On Track For Milestone Closes
Via Talk Markets
Topics Stocks
Exposures US Equities
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
Via Benzinga
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Via Benzinga
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
Via Benzinga
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
Via Benzinga
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.